Literature DB >> 20391500

Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies.

Lisa G Rider1, Deloris Koziol, Edward H Giannini, Minal S Jain, Michaele R Smith, Kristi Whitney-Mahoney, Brian M Feldman, Susan J Wright, Carol B Lindsley, Lauren M Pachman, Maria L Villalba, Daniel J Lovell, Suzanne L Bowyer, Paul H Plotz, Frederick W Miller, Jeanne E Hicks.   

Abstract

OBJECTIVE: To validate manual muscle testing (MMT) for strength assessment in juvenile and adult dermatomyositis (DM) and polymyositis (PM).
METHODS: Patients with PM/DM (73 children and 45 adults) were assessed at baseline and reevaluated 6-9 months later. We compared Total MMT (a group of 24 proximal, distal, and axial muscles) and Proximal MMT (7 proximal muscle groups) tested bilaterally on a 0-10 scale with 144 subsets of 6 and 96 subsets of 8 muscle groups tested unilaterally. Expert consensus was used to rank the best abbreviated MMT subsets for face validity and ease of assessment.
RESULTS: The Total, Proximal, and best MMT subsets had excellent internal reliability (Total MMT r(s) = 0.91-0.98), and consistency (Cronbach's alpha = 0.78-0.97). Inter- and intrarater reliability were acceptable (Kendall's W 0.68-0.76, r(s) = 0.84-0.95). MMT subset scores correlated highly with Total and Proximal MMT scores and with the Childhood Myositis Assessment Scale, and correlated moderately with physician global activity, functional disability, magnetic resonance imaging, and axial and distal MMT scores, and, in adults, with creatine kinase level. The standardized response mean for Total MMT was 0.56 in juveniles and 0.75 in adults. Consensus was reached to use a subset of 8 muscles (neck flexors, deltoids, biceps, wrist extensors, gluteus maximus and medius, quadriceps, and ankle dorsiflexors) that performed as well as the Total and Proximal MMT, and had good face validity and ease of assessment.
CONCLUSION: These findings aid in standardizing the use of MMT for assessing strength as an outcome measure for myositis.

Entities:  

Mesh:

Year:  2010        PMID: 20391500      PMCID: PMC2924143          DOI: 10.1002/acr.20035

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  20 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Evaluating measurement responsiveness.

Authors:  M H Liang
Journal:  J Rheumatol       Date:  1995-06       Impact factor: 4.666

3.  Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research.

Authors:  M H Liang; M G Larson; K E Cullen; J A Schwartz
Journal:  Arthritis Rheum       Date:  1985-05

4.  Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM).

Authors:  Minal Jain; Michaele Smith; Holly Cintas; Deloris Koziol; Robert Wesley; Michael Harris-Love; Dan Lovell; Lisa G Rider; Jeanne Hicks
Journal:  Phys Occup Ther Pediatr       Date:  2006       Impact factor: 2.360

5.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors:  D J Lovell; C B Lindsley; R M Rennebohm; S H Ballinger; S L Bowyer; E H Giannini; J E Hicks; J E Levinson; R Mier; L M Pachman; M H Passo; M D Perez; A M Reed; K N Schikler; M Smith; L S Zemel; L G Rider
Journal:  Arthritis Rheum       Date:  1999-10

Review 6.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

Authors:  F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

Review 7.  Defining Clinical Improvement in Adult and Juvenile Myositis.

Authors:  Lisa G Rider; Edward H Giannini; Michael Harris-Love; Galen Joe; David Isenberg; Clarissa Pilkington; Peter A Lachenbruch; Frederick W Miller
Journal:  J Rheumatol       Date:  2003-03       Impact factor: 4.666

Review 8.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

Review 9.  Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis.

Authors:  Nicolino Ruperto; Angelo Ravelli; Kevin J Murray; Daniel J Lovell; Boel Andersson-Gare; Brian M Feldman; Stella Garay; Wietse Kuis; Claudia Machado; Lauren Pachman; Anne-Marie Prieur; Lisa G Rider; Earl Silverman; Elena Tsitsami; Pat Woo; Edward H Giannini; Alberto Martini
Journal:  Rheumatology (Oxford)       Date:  2003-06-27       Impact factor: 7.580

10.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors:  L G Rider; B M Feldman; M D Perez; R M Rennebohm; C B Lindsley; L S Zemel; C A Wallace; S H Ballinger; S L Bowyer; A M Reed; M H Passo; I M Katona; F W Miller; P A Lachenbruch
Journal:  Arthritis Rheum       Date:  1997-11
View more
  65 in total

Review 1.  Update on the assessment of children with juvenile idiopathic inflammatory myopathy.

Authors:  Adam M Huber
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

2.  [Early symptoms of dermatomyositis and antisynthetase syndrome].

Authors:  B Maurer
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

3.  Whole-body MRI in adult inflammatory myopathies: Do we need imaging of the trunk?

Authors:  Lukas Filli; Britta Maurer; Andrei Manoliu; Gustav Andreisek; Roman Guggenberger
Journal:  Eur Radiol       Date:  2015-04-24       Impact factor: 5.315

Review 4.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

Review 5.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

Review 6.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 7.  Role of MRI in diagnosis and management of idiopathic inflammatory myopathies.

Authors:  Britta Maurer; Ulrich A Walker
Journal:  Curr Rheumatol Rep       Date:  2015-11       Impact factor: 4.592

8.  Clinico-serologic features of statin-induced necrotising autoimmune myopathy in a single-centre cohort.

Authors:  Michael J Waters; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

9.  A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies.

Authors:  Neil Martin; Petra Krol; Sally Smith; Kevin Murray; Clarissa A Pilkington; Joyce E Davidson; Lucy R Wedderburn
Journal:  Rheumatology (Oxford)       Date:  2010-09-07       Impact factor: 7.580

10.  Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.

Authors:  Rohit Aggarwal; Andriy Bandos; Ann M Reed; Dana P Ascherman; Richard J Barohn; Brian M Feldman; Frederick W Miller; Lisa G Rider; Michael O Harris-Love; Marc C Levesque; Chester V Oddis
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.